Alzheimer's disease is a growing challenge for care providers and purchasers. With the shift away from the provision of long term institutional care in most developed countries, there is a growing tendency for patients with Alzheimer's disease to be cared for at home. In the United Kingdom, this change of direction contrasts with the policies ofthe 1980s and 90s which focused more attention on controlling costs than on assessment of the needs of the patient and carer and patient management. In recent years, the resources available for management of Alzheimer's disease have focused on institutional care, coupled with drug treatment to control difficult behaviour as the disease progresses. For these reasons, the current system has led to crisis management rather than preventive support-that is, long term care for a few rather than assistance in the home before the crises occur and institutional care is needed. Despite recent innovations in the care of patients with Alzheimer's disease, the nature ofthe support that patients and carers receive is poorly defined and sometimes inadequate. As a result of the shift towards care in the community, the informal carer occupies an increasingly central role in the care of these patients and the issue of how the best quality of care may be defined and delivered is an issue which is now ripe for review. The objective of this paper is to redefine the type of support that patients and carers should receive so that the disease can be managed more effectively in the community. The needs of patients with Alzheimer's disease and their carers are many and this should be taken into account in defining the quality and structure of healthcare support. This paper shows how new initiatives, combined with recently available symptomatic drug treatment, can allow patients with Alzheimer's disease to be maintained at home for longer. This will have the dual impact of raising the quality of care for patients and improving the quality of life for their carers. Moreover, maintaining patients in a home environment will tend to limit public and private expenditure on institutional care due to a possible delay in the need for it.
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We begin by outlining the social and economic burden that Alzheimer's disease represents. This disease is the most common form of dementia and is associated with reduced life expectancy and considerable morbidity. Also, the economic burden on the NHS and social services is substantial, particularly in relation to institutional care which is more frequent as the disease progresses. The practical and financial burden has shifted to informal carers who now occupy a central role in maintaining patients in the community. Despite this, carers are not always well equipped to cope with the difficulties the disease creates. Unless informal carers are better able to carry this burden in the community, the cost to the NHS and social services will escalate beyond control.
The paper then considers new initiatives in care provision which will help to maintain patients with Alzheimer's disease at home. These show the attention that is being focused In the United Kingdom, more than 60% of elderly people with advanced cognitive deficits live in their homes in the community, and about a fifth of these live alone6 ( fig 1) ; in fact this is most likely to be an underestimate as mild cases of dementia were not included in this particular study. This represents a substantial burden for carers who frequently cope with limited professional support. 7 It is estimated that informal carers save the state between £15 and £24 billion per year by supporting dependents who would otherwise need institutional care. 8 As is the case in many other countries, the United Kingdom has had a tradition of long term inpatient care, but there is now a move away from permanent care provided by the NHS and local authorities. In the early 1980s, the government encouraged the use of private care beds by permitting social security to fund private nursing home and residential care. Between 1980 and 1990 this policy produced an increase in the number of elderly and chronically ill people living in private residential care beds of over 300%,9 and put a major burden on public spending. To reduce the growing cost burden the 1990 NHS and Community Care Act was introduced which discouraged admission to hospital and residential care until all other options have been explored; as a result the provision of care was shifted to patients and their families.
"Community care has changed from meaning care in the community to care by the community."
With this change of policy, the number of long term beds has been reduced by the NHS and local authorities ( fig 2) ."1 At the same time there has been an increase in the number of beds contracted from the private sector and this trend is likely to continue in the future. However, this policy has been introduced with no apparent cost shifting between health and social services: local authority provision is means tested and patients now bear the initial burden until their personal funds fall below a certain threshold. These changes threaten to create a care deficit with many more frail elderly people living in the community and a consequent rise in the pressure on informal carers that is, the patient's family and friends. 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 Year Figure 2 Provision of beds for the elderly and disabled has moved to the private sector.
Hunter, McGill, Bosanquet, Jc)hnOson These factors have so far limited the extent to which patients with Alzheimer's disease and their carers have been supported by health and social systems. The same is true for some other European countries. In Italy, for instance, a study reported an average of 22 months between the onset of symptoms and the first presentation to the general practitioner (GP).4
Financial cost and funding of care Disability arising from the progressive decline in cognitive function eventually limits normal functioning. Because of this, the care needed for the management of the disease targets two areas: the medical aspect (need for medical assessment and diagnosis, medication, etc) and the social aspect of the disease (provision of meals on wheels in the community, home care, etc).
Drug expenditure on Alzheimer's disease is clearly reported to be low. ' The fragmentation of funding and provision lity to raise local of services between health and local authorities ae cases the demand may increase financial accountability for each cannot be met. As a agency but it creates difficulties for the patient n of care is increas-and carer. It diffuses the responsibility for prorer. ' 25 26 viding and funding patient care and the net result is a greater burden on the informal carer S AND CARERS than might otherwise be necessary. In the south of England a community hospital is assessing care needs at an early stage of the disease.36 This hospital is developing an early intervention programme in which the lifestyle of individual patients with Alzheimer's disease is adapted to take account of handicap at an early stage in the illness. The aim of this scheme is to help preserve cognitive and functional skills for as long as possible, and to help patients to adjust to the progress of their disease. Each patient has his own "portfolio of care" which forms an effective system of providing good quality, individualized care which can be delivered by a wide range of helpers in various care settings.
Because of the central role of informal carers in the daily life of most patients with Alzheimer's disease, meeting the carer's needs is also an important determinant of the quality of care. The South Devon Carers Consortium is implementing a project37 which aims to raise awareness of the needs of carers within the primary healthcare team, and develop networks and services to meet these needs. The Merton and Sutton Community NHS Trust38 is also investigating this. As well as identification of carers, members of the primary healthcare teams aim to refer carers to specifically designed health promotion courses.
There are also examples of training initiatives directed at the carer. "Training and liaison for carers and care workers"39 is a project being developed by the Preston Hall Hospital in Maidstone. Information is provided for carers about health related issues, as well as courses in nursing and physiotherapy skills.
There are also many initiatives to improve staff training; for example, the Bradford Dementia Centre offers courses in "dementia mapping", involving practical, teaching, and interpersonal skills.
The effective implementation of care strategies is also an important dimension of quality in care and in some areas, local and health authorities are starting to work together to achieve this. Cambridge and Huntingdon Health Authority has drawn up a policy framework to clarify the respective roles of the local authority and the NHS in an attempt to stop patients "falling between the cracks" in provision of care. As in other regions, they recognise a hierarchy of care settings, with increasing specialization and intensity of care: own home, residential home, nursing home, hospital. The level of disability (mental and physical) as well as the burden on the carer determine the need; when the medical needs of a patient increase, they move up the scale3 and institutional care is more likely. In other words, admission to long term care is on the basis of defined need, rather than being dictated by the level of service.
For some health and local authorities, working together also means pooling budgets. The Crewkern carer project40 and the Bridgwater carers support scheme,4" supported by both the Carers National Association and the Red Cross, are two examples of carers' projects which receive financial support from both the health and social services. Each of these projects is based in primary care and involves about 40 general practitioners; they promote a range of services aimed at supporting the carer, including advice and information, organisation of carers support groups, supportive listening, and referrals for patients and carers.
RECENT DEVELOPMENTS IN DRUG THERAPY
The use of drug treatment in Alzheimer's disease is currently limited. Until recently there was no effective treatment to control the symptoms of the disease and, rather than treat the patient, drugs were used primarily to control difficult behaviour or limit depression which affects up to 30% of patients with Alzheimer's disease. 42 43 Because of this, neuroleptic and antidepressant drugs have been the mainstay of management by drug treatment to date.
Tacrine (an acetylcholinesterase inhibitor) was the first symptomatic drug for Alzheimer's disease to be launched, although safety concerns meant that it was not made available in the United Kingdom. More recently donepezil (Aricept), a new once daily acetylcholinesterase inhibitor developed for the symptomatic treatment of mild to moderately severe Alzheimer's disease, has been made available and is the only approved treatment for Alzheimer's disease in the United Kingdom. Well designed controlled clinical trials have proved the efficacy of Aricept in improving both cognitive function and global function of the patient. 44 The safety and tolerability profiles of this agent suggest that it will be well accepted by patients, and easy for care givers to administer. Aricept will thus offer new opportunities for helping patients live independently for longer and for relieving the stress of carers. As drug treatment is now available, early diagnosis of Alzheimer's disease should become a greater priority.
OPPORTUNITIES AND AGENDA
Several new initiatives have the potential to improve the care that patients with Alzheimer's disease receive. Although this creates opportunities for better quality care, this cannot be achieved with current approaches to patient management, and a considerable shift of emphasis will be needed:
There will be a need for improved diagnostic accuracy, particularly at general practitioner (GP) level. A recent survey by the Alzheimer's Disease Society among 2000 carers' found that 30% of patients with dementia were first thought to be depressed or considered to have age associated memory disorder rather than dementia. Moreover, 60% of patients who presented with memory problems had no cognitive assessment or memory tests, yet these clearly aid detection of the disease. 45 Patients must be identified by the healthcare system at an earlier stage of the disease than at present. With the advent of effective drug treatment the early diagnosis of Alzheimer's disease is important; treatment for early disease may delay the onset of symptoms and improve the quality of life of the patient and the carer. Early diagnosis may also rule out other causes of dementia which may be treatable and require different management. 45 The introduction of brief, easily used screening tests46 deserves consideration as a first step during the over 75s annual health check. Alternatively, the MMSE is widely used for cognitive assessment in both the United Kingdom and United States47 and has considerable value in the detection of progressive cognitive impairment. 48 New care programmes carry a cost and purchasers of health care will be concerned about their potential budgetary impact. Health and social services will not necessarily bear the burden of cost associated with the use of a drug such as Aricept. Because it may delay the loss of cognitive function associated with Alzheimer's disease, 49 Aricept is a drug which may reduce morbidity to such a degree that the need for institutional care is delayed without increasing life expectancy. In this situation the period for which this high cost element will be needed will be reduced or compressed5" resulting in a saving in resources.
As well as keeping the patient at home longer, improved cognitive and global function associated with drug treatment may also bring about a reduction in the numbers of hours of informal care required in the short term, and a reduction in the intensity or the amount of community support services-for example, less need for meals on wheels, fewer nurse visits, and reduced use of professional carers.
These kinds of savings have already been described with tacrine, which delayed entry into institutional care by up to nine months, and savings of 17% to 30% were reported.5" 52
Conclusions
The carer has a central and increasingly important role in the management of patients with Alzheimer's disease and this will increase in the future. For this to be sustainable, the provision of adequate professional support must be a part of any new contract between professional and informal care givers.
However, it is clear that the provision of quality care in a domestic or non-institutional setting cannot be achieved through the use of a "one size fits all" policy and the nature of good quality care has yet to be defined clearly. Fortunately, many valuable initiatives are being established which will help to overcome the problem of poor provision of services and coordination. These programmes would seem to complement drug treatment, which itself is likely to have an increased role in the next few years for patients with Alzheimer's disease. These tailored care packages can raise the quality of support available to both the patients and their carers, as each is an inseparable part of care in the community for Alzheimer's disease.
Although drug treatment has the potential for reducing the costs for local authorities, and to some degree the patient and career, the purchase of drug treatment lies within the NHS. To encourage the appropriate use of drug treatment on the basis of needs of patients and carers, local and health authorities may need to pool budgets so that a flexible care package can be developed which is tailored to the specific needs of the patient. To avoid disparities in the delivery of care, the development of care protocols will be essential.
The development of medical guidelines to ensure best standard practice and accurate differential diagnosis would be a decisive step towards improved management of Alzheimer's disease. The new initiatives which are currently being developed in care provision in the United Kingdom are promising but need proper evaluation as they are developed further as an integrated approach that combines medical and social care. Below are initiatives of high priority.
(1) The primary and secondary care sectors need to develop shared care protocols if patients are not to fall between the cracks that exist between care providers.
(2) The routine annual check of the elderly (over 75s) in the United Kingdom is not designed to detect Alzheimer's disease, although there is no reason why simple cognitive assessments should not be included.
(3) Management guidelines and protocols will be needed to support clinicians (particularly GPs) in the recognition and treatment of patients with Alzheimer's disease. This is likely to have implications for the role ofother professions in primary care, particularly nurses.
(4) There will be a need to exploit all aspects of care that are likely to enable patients to be cared for more successfully and for longer, at home.
It is clear that new approaches, from sheltered housing to new drug treatments, offer possibilities that were previously not available. No single approach will fit the needs of all patient-carer situations and a flexible, integrated approach to care provision and funding is likely to be the most successful. It is likely, however, that good community based care will be facilitated by specific Alzheimer drug treatments that are now becoming available.
The introduction of Aricept provides an opportunity to develop a more integrated pattern of care with a wider range of partners, as follows:
(1) Family doctors will not only be involved in prescribing but they will also be increasingly involved in providing and purchasing support services as fundholders. They will work more closely with colleagues such as community psychiatric nurses as well as other community nurses.
(2) Respite care in nursing homes could provide considerable help to carers and patients at a much lower cost than permanent institutional care.
(3) Community trusts can develop innovative models of day service and local rehabilitation. 
